<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151371">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01931189</url>
  </required_header>
  <id_info>
    <org_study_id>NI071A1</org_study_id>
    <nct_id>NCT01931189</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of NI-071</brief_title>
  <official_title>A Clinical Pharmacokinetics Study of NI-071</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nichi-Iko Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nichi-Iko Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess equivalence of pharmacokinetics between NI-071 and
      infliximab(the comparator) in Japanese healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>PK : Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUCt)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK : Area Under the Curve From Time Zero Extrapolated to Infinite Time (AUCinf)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : Incidence of Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : Incidence of Anti-Drug Antibodies(ADA)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NI-071</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NI-071</intervention_name>
    <description>100mg/vial</description>
    <arm_group_label>NI-071</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>100mg/vial</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects (healthy is defined as no clinically relevant abnormalities
             identified by a detailed medical history, clinical laboratory tests, etc.)

          2. Body Mass Index (BMI) of 18.5 to 25.0 kg/m2, and a total body weight of 50 to 80 kg

        Exclusion Criteria:

          1. Subjects with a following past History or concomitant diseases

               -  Chronic or recurrent infectious disease

               -  Demyelinating disease

               -  Congestive heart failure

               -  lymphoproliferative disorder or myelodysplastic syndrome

               -  Malignancy

               -  Interstitial lung disease

          2. Subjects with active or latent tuberculosis or history of tuberculosis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NichiIko Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For site information, send an email with site number to</last_name>
      <email>mori@nichiiko.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 8, 2013</lastchanged_date>
  <firstreceived_date>August 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
